Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Fukuoka, Masahiro; Wu, Yi‐Long; Thongprasert, Sumitra; Sunpaweravong, Patrapim; Leong, Swan-Swan; Sriuranpong, Virote; Chao, Tsu-Yi; Nakagawa, Kazuhiko; Chu, Da-Tong; Saijo, Nagahiro; Duffield, Emma; Rukazenkov, Yuri; Speake, Georgina; Jiang, Haiyi; Armour, Alison; To, Ka‐Fai; Chih‐Hsin Yang, James; Mok, Tony

doi:10.1200/jco.2010.33.4235

Public

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Published in Journal of Clinical Oncology • Jun 14, 2011

Authors:

Masahiro Fukuoka

Yi‐Long Wu

Sumitra Thongprasert

Abstract

PURPOSE: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy accordin...

Subject

Medicine

Gefitinib

Carboplatin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!